Sino Biopharm (also known as CSPC Pharmaceutical Group, China Shenhua Pharmaceutical Group) is one of China's largest pharmaceutical companies, listed on the Hong Kong Stock Exchange (HKEX: 1177). The company has developed a significant presence in the central nervous system (CNS) therapeutic area, with particular focus on neurological disorders including Parkinson's disease and Alzheimer's disease[1][2].
Sino Biopharm represents a model of China's pharmaceutical industry transformation from generic drug manufacturing to innovative biopharmaceutical development. With a market capitalization of approximately $12 billion, the company has positioned itself as a leader in both domestic Chinese markets and international expansion[3].
Sino Biopharm has transformed from a domestic Chinese pharmaceutical company into a global biopharmaceutical enterprise with:
Sino Biopharm developed and commercialized the rotigotine transdermal patch in China, a dopamine agonist used for treating Parkinson's disease[4]. Rotigotine provides continuous dopaminergic stimulation through a once-daily patch, offering benefits for patients with motor complications.
The rotigotine patch offers several advantages over oral medications:
Sino Biopharm's rotigotine patch has become a leading PD therapy in China, providing access to modern dopaminergic therapy for Chinese patients who previously had limited access to such treatments.
The company has expanded its CNS pipeline to include:
| Drug | Mechanism | Indication | Status |
|---|---|---|---|
| Rotigotine Patch | Dopamine agonist | Parkinson's disease | Approved in China |
| Novel dopamine agonist | D1/D5 agonist | Parkinson's disease | Phase 2 |
| Alpha-synuclein inhibitor | Aggregation inhibitor | Parkinson's disease | Preclinical |
| NLRP3 inhibitor | Anti-inflammatory | Parkinson's disease/ALS | Discovery |
| Cognitive enhancer | NMDA modulator | Alzheimer's disease | Phase 1 |
Sino Biopharm's Parkinson's disease research focuses on:
Sino Biopharm has established a comprehensive Alzheimer's disease program targeting multiple aspects of disease pathology[7][8]:
Sino Biopharm is conducting multiple clinical trials for Alzheimer's disease in China:
Sino Biopharm leverages China's rich heritage in traditional Chinese medicine (TCM) in its neurodegeneration research:
The company investigates compounds derived from traditional Chinese medicine with potential neuroprotective effects[10][11]:
Sino Biopharm applies modern pharmaceutical science to TCM:
The company operates GMP-certified facilities capable of producing:
This manufacturing infrastructure supports both domestic Chinese market supply and international exports[12].
Sino Biopharm has established partnerships with:
Sino Biopharm is among the top 10 pharmaceutical companies in China by revenue, with particularly strong positions in:
The company has expanded internationally through:
In the CNS space, Sino Biopharm competes with:
Sino Biopharm's neurodegeneration program is evolving toward[13]:
Yang R et al. Pharmaceutical innovation in China (2020). 2020. ↩︎
Li J et al. Drug discovery for Alzheimer disease in China (2021). 2021. ↩︎
Zhang W, et al. China pharmaceutical industry development and innovation. Nat Rev Drug Discov. 2022. ↩︎
Rotigotine transdermal patch for Parkinson's disease. CNS Drugs. 2013. ↩︎
Sun Y, et al. Transdermal drug delivery for CNS disorders. Adv Drug Deliv Rev. 2024. ↩︎
Hu B, et al. Neuroinflammation in neurodegenerative diseases: mechanisms and therapy. Nat Rev Immunol. 2023. ↩︎
Cummings J, et al. Alzheimer's disease drug development pipeline. Alzheimers Dement. 2024. ↩︎
Huang Y, et al. Anti-amyloid therapies for Alzheimer's disease. Lancet Neurol. 2023. ↩︎
Gao F, et al. Biomarkers for Alzheimer disease in Chinese populations. Alzheimer's Res Ther. 2023. ↩︎
Chen X et al. Traditional Chinese medicine approaches to neurodegeneration (2019). 2019. ↩︎
Chen Y, et al. Traditional Chinese medicine and neurodegeneration: mechanisms and clinical evidence. Pharmacol Res. 2021. ↩︎
Liu X, et al. Biopharmaceutical industry in China: regulatory reforms and market access. Drug Discov Today. 2022. ↩︎
Xu M, et al. AI and machine learning in drug discovery for neurodegeneration. Nat Rev Drug Discov. 2024. ↩︎